The aim of the study was to evaluate if and how varicella prevalence has changed in Italy. In particular a seroprevalence study was performed, comparing it to similar surveys conducted in pre-immunization era. During 2013-2014, sera obtained from blood samples taken for diagnostic purposes or routine investigations were collected in collaboration with at least one laboratory/Centre for each region, following the approval of the Ethics Committee. Data were stratified by sex and age. All samples were processed in a national reference laboratory by an immunoassay with high sensitivity and specificity. Statutory notifications, national hospital discharge database and mortality data related to VZV infection were analyzed as well. A total of 3707 sera were collected and tested. In the studied period both incidence and hospitalization rate decreased and about 5 deaths per year have been registered. The seroprevalence decreased in the first year of life in subjects passively protected by their mother, followed by an increase in the following age classes. The overall antibody prevalence was 84%. The comparison with surveys conducted with the same methodology in 1996-1997 and 2003-2004 showed significant differences in age groups 1-19 years. The study confirms that in Italy VZV infection typically occurs in children. The impact of varicella on Italian population is changing. The comparison between studies performed in different periods shows a significant increase of seropositivity in age class 1-4 years, expression of vaccine interventions already adopted in some regions.
Introduction
Worldwide, varicella (chickenpox) is an endemic, highly contagious, disease caused by a Herpesvirus called varicella-zoster virus (VZV). 1 In temperate climates, at least 90% of the population acquires the disease within 15 years of age (95% in adulthood). 2 In tropical countries, chickenpox has a lower incidence; primary infection is less frequent in children and mainly involves adult age groups, as a result of climatic factors that play a role in influencing the spreading of the virus. 3 Primary infection usually elicits a long lasting immune response which, anyway, cannot avoid neither virus' latency nor its subsequent reactivation after many years. Virus' reactivation is linked to a decrease of VZV-specific cellmediated response. 4 From the clinical point of view, varicella is often considered a benign disease. However, in 2-6% of cases some complications can occur. These latter are classified as infectious (cutaneous and soft tissue super-infections, bacterial pneumonia, etc.), neurological (cerebellitis, encephalitis, meningitis, etc.) and haematological (anemia, thrombocytopenic autoimmune purpura, etc.). 5 The majority of complications and hospitalizations due to chickenpox occurs in immunologically healthy children without any co-morbidity. 6 However, the severity of primary infection tends to increase with the age of the patient; the most severe clinical manifestations of the disease involve teenagers, adults and immunocompromised patients. 7 Several European studies show an incidence of hospitalization ranging between 1.3 and 4.5 for 100,000 inhabitants/year and 12.9-28.0/100,000 children ≤16 years of age/year, with an average length of stay ranging from 3 to 8 days.
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VZV infection in a susceptible pregnant woman is particularly worrying. The incidence of VZV in pregnancy is estimated equal to 1-7/10,000 pregnancies. 9 The virus acquired during the last trimester may result in an increased risk of pneumonia for the pregnant woman. demonstrated by seroprevalence studies. 5 The different social and educational structure of each country could explain differences, even significant, in the spread of the virus. 
Methods
A national cross-sectional population-based seroprevalence study of varicella antibodies was conducted.
The study was approved by the Ethics Committee of the Istituto Superiore di Sanità (ISS) in compliance with current regulations on the protection of personal data. 15 Anonymous unlinked samples of residual sera from routine laboratory testing, provided by a reference laboratory in each region, were collected. Samples from individuals known to have an immunosuppressive or acute infectious disease and those from individuals who had recently undergone a blood transfusion were excluded. All individuals who provided serum samples gave verbal informed consent; consent for minors was provided by parents or legal guardians.
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The number of sera to be collected for each age group (Table 1) was calculated using estimated antibody prevalence in that age-group obtained from a previous serology study. A minimum number of 3275 serum samples, equally distributed by gender, were to be collected.
Sera were stored at -20°C until tested by the laboratory of the University of Salento, Lecce, for varicella antibodies. Anti-VZV specific antibodies were detected using a commercially About 70% of the total hospitalizations due to varicella involved children (0-14 age group).
Results

Overall
Hospitalization rate was 42.9 per 100,000 population in children under one year of age, 26.6 in the 1-4 age group and 6.8 in the 5-14 age group. Mortality data showed an average of 4 and 6 deaths in the periods 2001-2010 and 2011-2012, respectively.
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Discussion
Universal vaccination against varicella, already adopted in many countries during childhood with the administration of two doses, allows to achieve significant results in terms of reduction of the virus spreading, impact on complications and hospitalizations, protection of high-risk subjects and disease related costs' savings.
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Essential prerequisite for the achievement of positive results is the early attainment and maintenance of high vaccine coverage rates to avoid indirect effects (such as the increase of the mean average age of infection and a higher risk of serious complications in older susceptible subjects that become infected). The effectiveness of immunization has also been demonstrated in a previous research where the changes in the seroepidemiological pattern were assessed in the same 8 "pilot" regions.
The increase in seroprevalence was most evident in the age groups target of immunization. 22 The data of the present study confirm that the impact of varicella on Italian population is changing. As a matter of fact, in comparison to data obtained in 1996-1997 and 2003-2004 the rate of seropositivity significantly increased in the age groups 1 and 2-4 years highlighting the crucial role played by immunization interventions already implemented in 8
"pilot" regions which, in terms of residents, represent the 37.2% of the Italian population. In the age group 5-19 years seroprevalence was higher in the remaining regions probably because of high circulation of varicella virus in absence of universal immunization strategy. 22 We must consider that the "late adopters" regions ( 
